A carregar...
Developmental Therapeutics in Myeloproliferative Neoplasms
The unprecedented success of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in myelofibrosis provided much-needed impetus for clinical drug development for the Philadelphia chromosome negative myeloproliferative neoplasms (MPN). The survival benefit conferred by this agent, along with its marked e...
Na minha lista:
| Publicado no: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5540010/ https://ncbi.nlm.nih.gov/pubmed/28760302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2017.02.014 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|